Management of pediatric hepatocellular carcinoma: A multimodal approach

Mira A. Kohorst; Deepti M. Warad; Jane M. Matsumoto; Julie K. Heimbach; Mounif El-Youssef; Carola A.S. Arndt; Vilmarie Rodriguez; Amulya A. Nageswara Rao

doi:10.1111/petr.13007

Management of pediatric hepatocellular carcinoma: A multimodal approach

Mira A. Kohorst, Deepti M. Warad, Jane M. Matsumoto, Julie K. Heimbach, Mounif El-Youssef, Carola A.S. Arndt, Vilmarie Rodriguez, Amulya A. Nageswara Rao

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

HCC is rare in the pediatric population, but is the second most common liver malignancy in children. Survival rates for primary unresectable HCC have been dismal. The objective of this study was to describe our experience with a multimodal approach for the management of unresectable HCC in two adolescent patients and to review the literature. Both patients are currently alive with no recurrence at 51 and 29 months post-transplant. Multimodality treatment involving chemotherapy with doxorubicin, cisplatin, and sorafenib; TACE; timely liver transplantation; and post-transplant therapy with sorafenib and mTOR inhibitors may help improve outcomes and prolong survival in pediatric patients with unresectable HCC.

Original language	English (US)
Article number	e13007
Journal	Pediatric Transplantation
Volume	21
Issue number	6
DOIs	https://doi.org/10.1111/petr.13007
State	Published - Sep 2017

Keywords

chemoembolization
hepatocellular carcinoma
liver transplant
pediatric
sorafenib

ASJC Scopus subject areas

Transplantation
Pediatrics, Perinatology, and Child Health

Access to Document

10.1111/petr.13007

Cite this

@article{7cca6e7cbb01495c8de7a96869263616,

title = "Management of pediatric hepatocellular carcinoma: A multimodal approach",

abstract = "HCC is rare in the pediatric population, but is the second most common liver malignancy in children. Survival rates for primary unresectable HCC have been dismal. The objective of this study was to describe our experience with a multimodal approach for the management of unresectable HCC in two adolescent patients and to review the literature. Both patients are currently alive with no recurrence at 51 and 29 months post-transplant. Multimodality treatment involving chemotherapy with doxorubicin, cisplatin, and sorafenib; TACE; timely liver transplantation; and post-transplant therapy with sorafenib and mTOR inhibitors may help improve outcomes and prolong survival in pediatric patients with unresectable HCC.",

keywords = "chemoembolization, hepatocellular carcinoma, liver transplant, pediatric, sorafenib",

author = "Kohorst, {Mira A.} and Warad, {Deepti M.} and Matsumoto, {Jane M.} and Heimbach, {Julie K.} and Mounif El-Youssef and Arndt, {Carola A.S.} and Vilmarie Rodriguez and {Nageswara Rao}, {Amulya A.}",

note = "Publisher Copyright: {\textcopyright} 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",

year = "2017",

month = sep,

doi = "10.1111/petr.13007",

language = "English (US)",

volume = "21",

journal = "Pediatric Transplantation",

issn = "1397-3142",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Management of pediatric hepatocellular carcinoma

T2 - A multimodal approach

AU - Kohorst, Mira A.

AU - Warad, Deepti M.

AU - Matsumoto, Jane M.

AU - Heimbach, Julie K.

AU - El-Youssef, Mounif

AU - Arndt, Carola A.S.

AU - Rodriguez, Vilmarie

AU - Nageswara Rao, Amulya A.

PY - 2017/9

Y1 - 2017/9

N2 - HCC is rare in the pediatric population, but is the second most common liver malignancy in children. Survival rates for primary unresectable HCC have been dismal. The objective of this study was to describe our experience with a multimodal approach for the management of unresectable HCC in two adolescent patients and to review the literature. Both patients are currently alive with no recurrence at 51 and 29 months post-transplant. Multimodality treatment involving chemotherapy with doxorubicin, cisplatin, and sorafenib; TACE; timely liver transplantation; and post-transplant therapy with sorafenib and mTOR inhibitors may help improve outcomes and prolong survival in pediatric patients with unresectable HCC.

AB - HCC is rare in the pediatric population, but is the second most common liver malignancy in children. Survival rates for primary unresectable HCC have been dismal. The objective of this study was to describe our experience with a multimodal approach for the management of unresectable HCC in two adolescent patients and to review the literature. Both patients are currently alive with no recurrence at 51 and 29 months post-transplant. Multimodality treatment involving chemotherapy with doxorubicin, cisplatin, and sorafenib; TACE; timely liver transplantation; and post-transplant therapy with sorafenib and mTOR inhibitors may help improve outcomes and prolong survival in pediatric patients with unresectable HCC.

KW - chemoembolization

KW - hepatocellular carcinoma

KW - liver transplant

KW - pediatric

KW - sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85021186292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021186292&partnerID=8YFLogxK

U2 - 10.1111/petr.13007

DO - 10.1111/petr.13007

M3 - Article

C2 - 28631359

AN - SCOPUS:85021186292

SN - 1397-3142

VL - 21

JO - Pediatric Transplantation

JF - Pediatric Transplantation

IS - 6

M1 - e13007

ER -

Management of pediatric hepatocellular carcinoma: A multimodal approach

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this